Grifols (+17.8%) is one of the best performing companies in the Ibex35 (+0.95%), and a top performer in AV’s pharma coverage (+0.99%) over the last one month. We attribute this outperformance to primarily two developments – the FDA approval of its 20% SCIg (Xembify) on 4 July 2019 and the presentation of the AMBAR (Alzheimer Management by Albumin Replacement) study result (for the treatment of Alzheimer’s disease) on 16 July 2019.
24 Jul 2019
Grifols sprints
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Grifols sprints
Grifols, S.A. Class A (GRF:WBO) | 0 0 1.0% | Mkt Cap: 14,874m
- Published:
24 Jul 2019 -
Author:
Kamla Singh -
Pages:
3
Grifols (+17.8%) is one of the best performing companies in the Ibex35 (+0.95%), and a top performer in AV’s pharma coverage (+0.99%) over the last one month. We attribute this outperformance to primarily two developments – the FDA approval of its 20% SCIg (Xembify) on 4 July 2019 and the presentation of the AMBAR (Alzheimer Management by Albumin Replacement) study result (for the treatment of Alzheimer’s disease) on 16 July 2019.